Condition

Nonalcoholic Fatty Liver Disease

ClinicalTrials.gov condition label

Clinical trials36
Recruiting5
Common interventions25
Lead sponsors shown15

Clinical trials

36 shown
iWAIST Trial: ERCG (Endoscopic Radial Compression Gastroplasty) vs Optimized Lifestyle Intervention for Weight LossNCT07237750 · 2026-03-01
RECRUITING
Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related DiseasesNCT07248371 · 2025-06-09
RECRUITING
Effect of Henagliflozein on Hepatic Fat Content in Patients With T2DM and NAFLDNCT06449833 · 2024-06-01
RECRUITING
Screening and Follow-up in Patients With HIV Infection Combined With Metabolic Associated Fatty Liver DiseaseNCT05330923 · 2022-01-01
RECRUITING
Non-Alcoholic Fatty Liver Disease in a Saudi Cohort With Type 2 Diabetes MellitusNCT05697991 · 2015-03-23
RECRUITING
Bariatric Embolization of Arteries for the Treatment of Nonalcoholic SteatohepatitisNCT02933554 · 2025-12-01
NOT_YET_RECRUITING
Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the USNCT05211284 · 2022-12-08
TERMINATED
Effectiveness of Endoscopic Sleeve Gastroplasty in Nonalcoholic Fatty Liver Disease/Nonalcoholic SteatohepatitisNCT05507151 · 2022-08-24
ACTIVE_NOT_RECRUITING
Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)NCT05459701 · 2022-05-01
COMPLETED
Time Restricted Feeding on Nonalcoholic Fatty Liver Disease ( TREATY-FLD )：a 12-month Follow-up StudyNCT04988230 · 2021-07-30
COMPLETED
Gut Microbiota in Chronic Noncommunicable DiseasesNCT04820556 · 2021-04-12
COMPLETED
Comparison of Dietary Sugar Reduction MethodsNCT04186793 · 2020-02-06
COMPLETED
Effect of Mediterranean Diet in Obese Adolescents With Nonalcoholic Fatty Liver DiseaseNCT04845373 · 2020-01-05
COMPLETED
Time Restricted Feeding on Nonalcoholic Fatty Liver DiseaseNCT03786523 · 2019-04-19
COMPLETED
De Novo Lipogenesis in Severity of NAFLDNCT03683589 · 2019-02-01
COMPLETED
A Study of HTD1801 in Adults With Nonalcoholic Steatohepatitis (NASH) and Type 2 Diabetes Mellitus (T2DM)NCT03656744 · 2018-11-26
COMPLETED
Diabetes Prevention Program for the Treatment of Nonalcoholic Fatty Liver DiseaseNCT04988204 · 2018-10-03
COMPLETED
A Phase 1a/1b Study of CB4211 in Healthy Non-obese Subjects and Subjects With Nonalcoholic Fatty Liver DiseaseNCT03998514 · 2018-07-09
COMPLETED
Effects of Exercise on Patients With Nonalcoholic Fatty Liver Disease- A Comparative Randomized Controlled TrialNCT03774511 · 2017-07-09
COMPLETED
Aramchol for HIV-associated Nonalcoholic Fatty Liver Disease and LipodystrophyNCT02684591 · 2016-01-01
COMPLETED
Controlled Trial of WLS vs. CLI for Severely Obese Adolescents With NASHNCT02412540 · 2015-04-23
COMPLETED
Fatty Liver Disease in Obese ChildrenNCT02117700 · 2015-04-01
COMPLETED
Hepatic Dysfunction, Vitamin D Status, and Glycemic Control in DiabetesNCT02132442 · 2014-03-01
COMPLETED
Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic SteatohepatitisNCT01934777 · 2013-10-01
COMPLETED
Impact of Bariatric Surgery on Nonalcoholic Fatty Liver DiseaseNCT01828528 · 2013-04-01
COMPLETED
High Fructose Corn SyrupNCT02018237 · 2012-03-01
COMPLETED
Long-term Investigation of Resveratrol on Fat Metabolism in Obese Men With Nonalcoholic Fatty Liver DiseaseNCT01446276 · 2011-11-01
COMPLETED
Study of Liraglutide Versus Insulin on Liver Fat Fraction in Patients With Type 2 DiabetesNCT01399645 · 2011-05-01
COMPLETED
Abundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD)NCT00983463 · 2009-10-01
ENROLLING_BY_INVITATION
Effects of Docosahexaenoic Acid (DHA) on Children With Nonalcoholic Fatty Liver Disease (NAFLD)NCT00885313 · 2009-03-01
COMPLETED
Alcohol Consumption and Type 2 Diabetes Mellitus Risk in Nonalcoholic Fatty Liver DiseaseNCT03847116 · 2009-01-01
COMPLETED
University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial)NCT00994682 · 2008-12-01
COMPLETED
Role of Pioglitazone and Berberine in Treatment of Non-Alcoholic Fatty Liver DiseaseNCT00633282 · 2008-03-01
COMPLETED
Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver DiseaseNCT01006889 · 2008-01-01
COMPLETED
Weight Gain After Smoking Cessation and NAFLDNCT05550688 · 2007-01-01
COMPLETED
LAGB as a Treatment for Morbid Obesity in AdolescentsNCT01045499 · 2005-09-13
COMPLETED

Common interventions

PlaceboDRUG6Continuous Energy RestrictionBEHAVIORAL2PlaceboOTHER2Time restricted feedingBEHAVIORAL2AramcholDRUG1berberineDRUG1CB4211 Dose 1DRUG1CB4211 Dose 2DRUG1CB4211 Dose 3DRUG1CB4211 Dose 4DRUG1CB4211 Dose 5DRUG1CB4211 Dose 6DRUG1CB4211 Dose TBDDRUG1Comprehensive Lifestyle InterventionBEHAVIORAL1Control diet: Low fat dietOTHER1Dapagliflozin 10mg TabDRUG1DHA250DRUG1DHA500DRUG1Diabetes Prevention ProgramBEHAVIORAL1Diet Provision GroupOTHER1Docosahexaenoic Acid plus Vitamin E plus cholineDRUG1Embospheres MicrospheresDEVICE1Endoscopic Radial Compression GastroplastyPROCEDURE1Endoscopic Sleeve GastroplastyPROCEDURE1Ergocalciferol, placeboDIETARY_SUPPLEMENT1

Trial status mix

COMPLETED27
RECRUITING5
ACTIVE_NOT_RECRUITING1
ENROLLING_BY_INVITATION1
NOT_YET_RECRUITING1
TERMINATED1

Phase mix

NA12
PHASE27
PHASE44
PHASE13
PHASE32

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.